ID: ALA4643585

Max Phase: Preclinical

Molecular Formula: C29H30O6

Molecular Weight: 474.55

Molecule Type: Unknown

Representations

Canonical SMILES:  CC1=C2[C@@H](CC1)[C@]1(C)O[C@@](c3ccccc3)(C[C@H]1OC(=O)CO)[C@H]2OC(=O)/C=C/c1ccccc1

Standard InChI:  InChI=1S/C29H30O6/c1-19-13-15-22-26(19)27(34-24(31)16-14-20-9-5-3-6-10-20)29(21-11-7-4-8-12-21)17-23(28(22,2)35-29)33-25(32)18-30/h3-12,14,16,22-23,27,30H,13,15,17-18H2,1-2H3/b16-14+/t22-,23-,27+,28+,29-/m1/s1

Standard InChI Key:  HMIZTNJYJQQHJM-YDIXTDQRSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Unknown

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 474.55

Molecular Weight (Monoisotopic): 474.2042

AlogP: 4.33

#Rotatable Bonds: 6

Polar Surface Area: 82.06

Molecular Species: NEUTRAL

HBA: 6

HBD: 1

#RO5 Violations: 0

HBA (Lipinski): 6

HBD (Lipinski): 1

#RO5 Violations (Lipinski): 0

CX Acidic pKa: 13.13

CX Basic pKa:

CX LogP: 4.49

CX LogD: 4.49

Aromatic Rings: 2

Heavy Atoms: 35

QED Weighted: 0.38

Np Likeness Score: 1.61

References

1. Wu Z, Suppo JS, Tumova S, Strope J, Bravo F, Moy M, Weinstein ES, Peer CJ, Figg WD, Chain WJ, Echavarren AM, Beech DJ, Beutler JA..  (2020)  Bridgehead Modifications of Englerin A Reduce TRPC4 Activity and Intravenous Toxicity but not Cell Growth Inhibition.,  11  (9): [PMID:32944138] [10.1021/acsmedchemlett.0c00186]

Source

Source(1):

• Scientific Literature